Literature DB >> 23297321

Can neutrophil gelatinase-associated lipocalin help depict early contrast material-induced nephropathy?

Antonio Lacquaniti1, Francesco Buemi, Rosaria Lupica, Claudio Giardina, Gabriella Murè, Adriana Arena, Carmela Visalli, Sergio Baldari, Carmela Aloisi, Michele Buemi.   

Abstract

PURPOSE: To evaluate the utility of serum and urinary neutrophil gelatinase-associated lipocalin (NGAL) in depicting an event of contrast material-induced nephropathy (CIN) in patients who received iodinated contrast media, gadoterate meglumine, or radiopharmaceutical technetium-99m ((99m)Tc) and to evaluate the protective effect exerted by isotonic saline infusion, sodium bicarbonate administration, or N-acetylcysteine administration.
MATERIALS AND METHODS: Institutional ethics committee approval was given, and informed consent was obtained. One hundred twenty patients were enrolled in a prospective study and divided into three groups: iomeprol group, magnetic resonance (MR) imaging group (gadoterate meglumine), and renal scintigraphy group ((99m)Tc). They randomly received N-acetylcysteine, physiologic saline, or sodium bicarbonate. Receiver operating characteristic (ROC) analysis, Kaplan-Meier curves, and Cox proportional hazard regression analysis were used.
RESULTS: In the MR imaging and renal scintigraphy groups, there were significant changes in serum creatinine and NGAL levels, and there were no cases of CIN. In the iomeprol group, an early rise in NGAL was found, while serum creatinine level changes occurred 24 hours after contrast material administration. At ROC analysis, NGAL showed high sensitivity and specificity (serum NGAL: area under the curve, 0.995; 95% confidence interval [CI]: 0.868, 0.992; urinary NGAL: area under the curve, 0.992; 95% CI: 0.925, 1.000) in identifying CIN 8 hours after iomeprol administration. Regression analysis showed that NGAL independently predicted CIN. Administration of N-acetylcysteine, sodium bicarbonate, or physiologic saline did not influence NGAL level.
CONCLUSION: NGAL depicted CIN in patients who received iodinated contrast material within 8 hours of contrast material administration. SUPPLEMENTAL MATERIAL: http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.12120578/-/DC1. RSNA, 2013

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23297321     DOI: 10.1148/radiol.12120578

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  14 in total

1.  Effect of iodinated contrast medium in diabetic rat kidneys as evaluated by blood-oxygenation-level-dependent magnetic resonance imaging and urinary neutrophil gelatinase-associated lipocalin.

Authors:  Lu-Ping Li; Jing Lu; Tammy Franklin; Ying Zhou; Richard Solomon; Pottumarthi V Prasad
Journal:  Invest Radiol       Date:  2015-06       Impact factor: 6.016

2.  Evaluation of intrarenal oxygenation in iodinated contrast-induced acute kidney injury-susceptible rats by blood oxygen level-dependent magnetic resonance imaging.

Authors:  Lu-Ping Li; Jing Lu; Ying Zhou; Maria V Papadopoulou; Tammy Franklin; Ujala Bokhary; Richard Solomon; Anindya Sen; Pottumarthi V Prasad
Journal:  Invest Radiol       Date:  2014-06       Impact factor: 6.016

Review 3.  Understanding and preventing contrast-induced acute kidney injury.

Authors:  Michael Fähling; Erdmann Seeliger; Andreas Patzak; Pontus B Persson
Journal:  Nat Rev Nephrol       Date:  2017-01-31       Impact factor: 28.314

4.  Role of urine neutrophil gelatinase-associated lipocalin in the early diagnosis of amphotericin B-induced acute kidney injury.

Authors:  Paulo Novis Rocha; Michael Nascimento Macedo; Carla Dinamérica Kobayashi; Lis Moreno; Luiz Henrique Santos Guimarães; Paulo Roberto Lima Machado; Roberto Badaró; Edgar M Carvalho; Marshall Jay Glesby
Journal:  Antimicrob Agents Chemother       Date:  2015-08-24       Impact factor: 5.191

5.  Efficacy of preventive interventions for iodinated contrast-induced acute kidney injury evaluated by intrarenal oxygenation as an early marker.

Authors:  Lu-Ping Li; Jon Thacker; Jing Lu; Tammy Franklin; Ying Zhou; Maria V Papadopoulou; Richard Solomon; Pottumarthi V Prasad
Journal:  Invest Radiol       Date:  2014-10       Impact factor: 6.016

Review 6.  Aging Male Spontaneously Hypertensive Rat as an Animal Model for the Evaluation of the Interplay between Contrast-Induced Acute Kidney Injury and Cardiorenal Syndrome in Humans.

Authors:  Jun Zhang; Mohammad Kazem Fallahzadeh; Peter A McCullough
Journal:  Cardiorenal Med       Date:  2016-07-21       Impact factor: 2.041

7.  No increase in Kidney Injury Molecule-1 and Neutrophil Gelatinase-Associated Lipocalin excretion following intravenous contrast enhanced-CT.

Authors:  Judith Kooiman; Wilke R van de Peppel; Yvo W J Sijpkens; Harald F H Brulez; P M de Vries; Mioara A Nicolaie; H Putter; Menno V Huisman; W van der Kooij; Cees van Kooten; Ton J Rabelink
Journal:  Eur Radiol       Date:  2015-03-15       Impact factor: 5.315

8.  The role of neutrophil-gelatinase-associated lipocalin in early diagnosis of contrast nephropathy.

Authors:  M R Khatami; M R P Sabbagh; N Nikravan; Z Khazaeipour; M A Boroumand; S Sadeghian; B Davoudi
Journal:  Indian J Nephrol       Date:  2015 Sep-Oct

9.  Neutrophil gelatinase-associated lipocalin (NGAL) fails as an early predictor of contrast induced nephropathy in chronic kidney disease (ANTI-CI-AKI study).

Authors:  Werner Ribitsch; Gernot Schilcher; Franz Quehenberger; Stefan Pilz; Rupert H Portugaller; Martini Truschnig-Wilders; Robert Zweiker; Marianne Brodmann; Philipp Stiegler; Alexander R Rosenkranz; John W Pickering; Joerg H Horina
Journal:  Sci Rep       Date:  2017-01-27       Impact factor: 4.379

10.  Urine/Plasma Neutrophil Gelatinase Associated Lipocalin Ratio Is a Sensitive and Specific Marker of Subclinical Acute Kidney Injury in Mice.

Authors:  Tamás Kaucsár; Mária Godó; Csaba Révész; Miklós Kovács; Attila Mócsai; Norbert Kiss; Mihály Albert; Tibor Krenács; Gábor Szénási; Péter Hamar
Journal:  PLoS One       Date:  2016-01-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.